Jeffrey Beal, MD
Internal Medicine · Ocean Grove, NJNPI 1801891437
Payments from drug & device makers
Across 67 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$155
- Lilly USA, LLC$119
- AbbVie$106
- AstraZeneca$89
- Novo Nordisk$78
- Pfizer$77
- plus $418 from 19 others
What the payments were for
- Food & beverage$1,042100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 7 | $155 |
| Lilly USA, LLC | 8 | $119 |
| AbbVie | 7 | $106 |
| AstraZeneca | 6 | $89 |
| Novo Nordisk | 5 | $78 |
| Pfizer | 6 | $77 |
| Lundbeck LLC | 3 | $52 |
| Merck | 3 | $41 |
| Bayer | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| GSK | 2 | $27 |
| Johnson & Johnson | 2 | $27 |
| Otsuka America Pharmaceutical, Inc. | 2 | $24 |
| Topcon Healthcare Solutions, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Vanda Pharmaceuticals Inc. | 1 | $13 |
| Vivus LLC | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
How this compares
$1,042 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $82,981 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $56,943 |
| OzempicSemaglutide | 52 | $50,475 |
| XareltoRivaroxaban | 74 | $35,518 |
| JanuviaSitagliptin Phosphate | 29 | $33,726 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $20,971 |
| NucyntaTapentadol Hcl | 12 | $17,310 |
| JardianceEmpagliflozin | 14 | $13,229 |
| TrulicityDulaglutide | 11 | $10,521 |
| FarxigaDapagliflozin Propanediol | 14 | $7,970 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $7,425 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $7,032 |
| Spiriva RespimatTiotropium Bromide | 14 | $6,701 |
| MovantikNaloxegol Oxalate | 13 | $5,700 |
| BelsomraSuvorexant | 11 | $4,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Dilantin | $77 | $85,736137 claims |
| Novo NordiskOzempic | $78 | $50,47552 claims |
| MerckJanuvia, Belsomra | $41 | $38,50940 claims |
| Johnson & JohnsonXarelto | $27 | $35,51874 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $27 | $28,39741 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $16 | $19,93028 claims |
| Lilly USA, LLCTrulicity | $119 | $10,52111 claims |
| AstraZenecaFarxiga | $89 | $7,97014 claims |
| AbbVieSynthroid | $106 | $2,52424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Ocean Grove
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.